A New Era: Drug Development for Acute Myeloid Leukemia After the Approval of Venetoclax
Although the 7 + 3 regimen has been the standard of care for acute myeloid leukemia for decades, it may be time to reassess its value and utility.
Although the 7 + 3 regimen has been the standard of care for acute myeloid leukemia for decades, it may be time to reassess its value and utility.
The model stratified patients into 3 risk groups based on median time to disease progression.
A decrease in gait speed by 0.1 m/s was associated with increases in mortality and utilization of emergency and acute care.
Platelet aggregation and platelet activation were both independently associated with bleeding risk.
Trastuzumab emtansine reduces the risk of recurrence by 50% in some HER2-positive breast cancers following neoadjuvant chemotherapy.
Poor prognostic factors for patients with EMZL include age greater than 70 years, advanced Ann Arbor stage, and elevated lactate dehydrogenase (LDH)
Septic shock is a leading cause of death in chemotherapy-treated patients with neutropenia, and updated guidelines for managing sepsis in this setting were recently published in Annals of Hematology.